Trial Profile
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Sotigalimab (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Apexigen
- 03 Aug 2023 Results (n=38) for safety, published in the Clinical Cancer Research
- 12 Nov 2021 Results published in the Apexigen Media Release.
- 12 Nov 2021 According to an Apexigen media release, data from this study was presented at the 36th Society for Immunotherapy of Cancers (SITC) Annual Meeting.